Video
Author(s):
Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.
Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.
Based on level 1 evidence, there is good data to support the use of pertuzumab (Perjeta) plus trastuzumab (Herceptin) with chemotherapy in the first line setting. This is then followed by T-DM1 in the second line, states Pegram.
This has set the standard of care for the HER2-postive metastatic breast cancer patient population, explains Pegram.